1 / 8

Session 4 - Communities of practice Natural Products Drug Discovery The ICBG Program: A view from afar *

Session 4 - Communities of practice Natural Products Drug Discovery The ICBG Program: A view from afar *. Special thanks to Joshua Rosenthal of the NIH Fogarty Center for his helpful discussions and figures on the ICBG program. Program goals and accomplishments.

perry
Download Presentation

Session 4 - Communities of practice Natural Products Drug Discovery The ICBG Program: A view from afar *

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Session 4 - Communities of practiceNatural Products Drug DiscoveryThe ICBG Program: A view from afar* Special thanks to Joshua Rosenthal of the NIH Fogarty Center for his helpful discussions and figures on the ICBG program

  2. Program goals and accomplishments • International Cooperative Biodiversity Groups • Biodiversity exploration • Scientific and economic development • Biodiversity conservation • Modeled on CBD ABS and Merck/InBIO agreement • PIC, IP, and benefit sharing Objectives • Competitive research grants (NIH/NSF/USDA) • Five years, $300 – 600k/year direct costs • Groups required academic institution and/or NFP, partner country, industrial partner Implementation • Managing expectations • Technology vs. sociology The grand challenge

  3. State of the field • Competing technologies and strategies • Combinatorial chemistry • HTP and UHTP screening • Therapeutic targets/privileged stuctures • Economic pressures • Decline in new chemical entities • Biodiversity as a commodity Commercial • Uncertainty of access • Uncertainty of provenance • Uncertainty of benefit Political

  4. Screening cultures Patent Scale-up Plants Animals Fermentation New product Solvent extraction Strain improvement Clinical Trials Chemical isolation Primary assays Safety Assessment Structure Toxicology Biocatalysis Medicinal chemistry Secondary assays Synthetic compounds Pharmacology Biocatalysis Dereplication Microbial Bioprospecting

  5. Reality check # 1 David J. Newman, NCI/NIH, 2005 Unpublished

  6. Reality check # 2 Baltz, R., Microbe 2007 2:125-131

  7. Outcomes Other benefits Drug discovery • >12,000+ spp collected • >1300 bioactive compounds isolated • >4000 people trained (350 long term) • Institutional capacity built in 16 countries • Informed bioprospecting policies in at least 6 countries • Initiated/ strengthened biodiversity reserves in 7 countries • Tested models of intellectual property rights and benefit-sharing/Established 14 Trust Funds • >500 publications • 14 years • $50 M (US govt) • 12 groups • 7 companies • 21 countries • 12,000 species • 1500 bioactive compounds • 0 drugs

  8. Market size Approx. $100B From A. Kuo and G.M.Garrity 2002 Exploiting Microbial Diversity, In Biodiversity of Microbial Life, J.T. Staley and A-L Reysenbach, ed, John Wiley

More Related